Gold nanocarriers for transport of oligonucleotides across brain endothelial cells.


Journal

PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081

Informations de publication

Date de publication:
2020
Historique:
received: 07 07 2020
accepted: 31 08 2020
entrez: 17 9 2020
pubmed: 18 9 2020
medline: 22 10 2020
Statut: epublish

Résumé

Treatment of diseases that affect the CNS by gene therapy requires delivery of oligonucleotides to target cells within the brain. As the blood brain barrier prevents movement of large biomolecules, current approaches involve direct injection of the oligonucleotides, which is invasive and may have only a localised effect. The aim of this study was to investigate the potential of 2 nm galactose-coated gold nanoparticles (NP-Gal) as a delivery system of oligonucleotides across brain endothelium. DNA oligonucleotides of different types were attached to NP-Gal by the place exchange reaction and were characterised by EMSA (electrophoretic mobility shift assay). Several nanoparticle formulations were created, with single- or double-stranded (20nt or 40nt) DNA oligonucleotides, or with different amounts of DNA attached to the carriers. These nanocarriers were applied to transwell cultures of human brain endothelium in vitro (hCMEC/D3 cell-line) or to a 3D-hydrogel model of the blood-brain barrier including astrocytes. Transfer rates were measured by quantitative electron microscopy for the nanoparticles and qPCR for DNA. Despite the increase in nanoparticle size caused by attachment of oligonucleotides to the NP-Gal carrier, the rates of endocytosis and transcytosis of nanoparticles were both considerably increased when they carried an oligonucleotide cargo. Carriers with 40nt dsDNA were most efficient, accumulating in vesicles, in the cytosol and beneath the basal membrane of the endothelium. The oligonucleotide cargo remained attached to the nanocarriers during transcytosis and the transport rate across the endothelial cells was increased at least 50fold compared with free DNA. The nanoparticles entered the extracellular matrix and were taken up by the astrocytes in biologically functional amounts. Attachment of DNA confers a strong negative charge to the nanoparticles which may explain the enhanced binding to the endothelium and transcytosis by both vesicular transport and the transmembrane/cytosol pathway. These gold nanoparticles have the potential to transport therapeutic amounts of nucleic acids into the CNS.

Identifiants

pubmed: 32941446
doi: 10.1371/journal.pone.0236611
pii: PONE-D-20-21009
pmc: PMC7498062
doi:

Substances chimiques

Oligodeoxyribonucleotides 0
Gold 7440-57-5
Galactose X2RN3Q8DNE

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0236611

Déclaration de conflit d'intérêts

The authors declared that no competing interests exist.

Références

Nat Rev Drug Discov. 2018 Sep;17(9):641-659
pubmed: 30093643
Anal Chem. 1999 Jun 1;71(11):2085-91
pubmed: 21662743
Nanoscale. 2014 Feb 21;6(4):2146-52
pubmed: 24362586
Nanotoxicology. 2019 Sep;13(7):990-1004
pubmed: 31106633
J Phys Chem B. 2010 Mar 4;114(8):2749-54
pubmed: 20146444
Annu Rev Biomed Eng. 2007;9:121-67
pubmed: 17373886
Neuroscience. 1980;5(7):1151-9
pubmed: 7402464
Adv Drug Deliv Rev. 2015 Jun 29;87:90-103
pubmed: 25797014
Nanomedicine (Lond). 2016 Mar;11(6):617-25
pubmed: 26911484
ACS Nano. 2015 Oct 27;9(10):9986-93
pubmed: 26435075
FASEB J. 2005 Nov;19(13):1872-4
pubmed: 16141364
Mol Ther. 2014 Jun;22(6):1075-1083
pubmed: 24599278
Nanoscale. 2012 Aug 7;4(15):4470-2
pubmed: 22743818
Mol Biol Cell. 2015 Feb 15;26(4):797-804
pubmed: 25518937
Ther Adv Neurol Disord. 2018 May 23;11:1756286418776932
pubmed: 29854003
Nano Lett. 2013 Sep 11;13(9):4060-7
pubmed: 23915118
Nanomaterials (Basel). 2019 Mar 05;9(3):
pubmed: 30841578
Gene Ther. 2013 Apr;20(4):450-9
pubmed: 23303281
Nat Mater. 2008 Jul;7(7):588-95
pubmed: 18500347
Nucleic Acids Res. 2016 Aug 19;44(14):6518-48
pubmed: 27084936
Curr Protoc Nucleic Acid Chem. 2002 Aug;Chapter 12:Unit 12.2
pubmed: 18428889
Eur J Biochem. 2000 Sep;267(17):5421-6
pubmed: 10951200
J Nanopart Res. 2010 Sep;12(7):2313-2333
pubmed: 21170131
J Control Release. 2016 Oct 28;240:251-266
pubmed: 26724368
Front Mol Neurosci. 2019 Jun 19;12:156
pubmed: 31275113
ACS Nano. 2008 Aug;2(8):1639-44
pubmed: 19206367
F1000Res. 2015 Nov 17;4:1279
pubmed: 26870320
J Nanobiotechnology. 2015 Oct 21;13:71
pubmed: 26489846
Methods Mol Biol. 2020;2056:269-284
pubmed: 31586354
Int Rev Neurobiol. 2016;130:155-98
pubmed: 27678177
Chem Soc Rev. 2017 Jul 17;46(14):4218-4244
pubmed: 28585944
PLoS One. 2013 Dec 05;8(12):e81043
pubmed: 24339894
PLoS One. 2016 Aug 25;11(8):e0161610
pubmed: 27560685
Nano Lett. 2006 Apr;6(4):662-8
pubmed: 16608261

Auteurs

Nayab Fatima (N)

Department of Life, Health and Chemical Sciences, The Open University, Milton Keynes, United Kingdom.

Radka Gromnicova (R)

Department of Life, Health and Chemical Sciences, The Open University, Milton Keynes, United Kingdom.

Jane Loughlin (J)

Department of Life, Health and Chemical Sciences, The Open University, Milton Keynes, United Kingdom.

Basil Sharrack (B)

Academic Department of Neuroscience and Sheffield, NIHR Translational Neuroscience BRC, Sheffield Teaching Hospitals, NHS Foundation Trust, University of Sheffield, Sheffield, United Kingdom.

David Male (D)

Department of Life, Health and Chemical Sciences, The Open University, Milton Keynes, United Kingdom.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH